Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 27;15(1):480.
doi: 10.1007/s12672-024-01376-4.

Recent progress in microRNA research for prostate cancer

Fan Yuan #  1 , Yue Hu #  2 , Yanmei Lei  3 , Lingna Jin  4
Affiliations
Review

Recent progress in microRNA research for prostate cancer

Fan Yuan et al. Discov Oncol. .

Abstract

In recent years, prostate cancer (PCa) has seen an increasing prevalence, particularly among middle-aged and older men, positioning it as a significant health concern. Current PCa screening predominantly utilizes prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and the Gleason scoring system. However, these diagnostic methods can sometimes be imprecise. Research has identified that specific microRNAs (miRNAs) exhibit altered expression levels in PCa patients, suggesting their potential as biomarkers for both diagnosis and prognosis. Furthermore, advancements in integrating miRNAs with traditional Chinese medicine (TCM) have shown promising results in PCa treatment, potentially serving as micro-markers for TCM syndrome differentiation and treatment effectiveness. Recent developments in anti-cancer therapies that target miRNAs have also been implemented in clinical settings, laying the groundwork for personalized and precise treatment strategies for PCa. This review aims to summarize the expression patterns of miRNAs in PCa patients and explore their roles in the diagnosis, treatment, and prognosis of the disease.

Keywords: Diagnose; MicroRNA; Prognosis; Prostate cancer; Traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The mechanism of action of miRNAs
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Gao R, et al. Clinical features and epidemiological trend of prostate cancer in the Changsha area of Hunan Province: Analysis of 2 877 cases. Natl J Androl. 2020;26(4):309–15. - PubMed
    1. Jiang G, et al. Morbidity and death trend of prostatic carcinoma, Qiannan, 2009–2018. Modern Preventive Medicine. 2019;46(13):2488–91.
    1. Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl. 2006;78(4):125–9. - PubMed
    1. Ceder Y. Non-coding RNAs in prostate cancer: from discovery to clinical applications. Adv Exp Med Biol. 2016;886:155–70. - PubMed

LinkOut - more resources